Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Opportunities and challenges in using real-world data for health care
Vivek A. Rudrapatna, Atul J. Butte
Vivek A. Rudrapatna, Atul J. Butte
Published February 3, 2020
Citation Information: J Clin Invest. 2020;130(2):565-574. https://doi.org/10.1172/JCI129197.
View: Text | PDF
Review Series

Opportunities and challenges in using real-world data for health care

  • Text
  • PDF
Abstract

Real-world data (RWD) continue to emerge as a new source of clinical evidence. Although the best-known use case of RWD has been in drug regulation, RWD are being generated and used by many other parties, including biopharmaceutical companies, payors, clinical researchers, providers, and patients. In this Review, we describe 21 potential uses for RWD across the spectrum of health care. We also discuss important challenges and limitations relevant to the translation of these data into evidence.

Authors

Vivek A. Rudrapatna, Atul J. Butte

×

Figure 1

Participants in the health care ecosystem that generate and consume health care data.

Options: View larger image (or click on image) Download as PowerPoint
Participants in the health care ecosystem that generate and consume heal...
Patients (and the communities they constitute) are the fundamental source of all clinical data. Much of the clinical data they generate emanates from clinic visits with health care providers. They also generate data from the pharmacies they purchase treatments from, the registries they participate in, and their use of modern/evolving technologies such as social media and wearables. In the setting of a traditional or telehealth-based encounter, clinical data in the form of laboratory test results, imaging, and notes are all generated and housed with an EHR system. These data may be repackaged and sent to managed care organizations and health care payors to facilitate reimbursement. These payors also transmit data relevant to drug benefits to pharmacy benefit managers (PBMs), who negotiate payment for drugs dispensed in pharmacies. Quality data from the EHR are also used by accountable care organizations (ACOs) to support certain quality-based reimbursement schemes. EHR data are also consumed by clinical researchers, individuals who oversee health care operations, and data aggregators. The latter deidentify and repackage these data for consumption by a variety of parties, including biopharmaceutical companies and regulators, as relevant for monitoring of treatment safety and efficacy, among other uses. Although most patient data represent a form of RWD, some patient data are collected in the setting of controlled trials. Although data from cardiac devices (e.g., pacemakers/cardioverter-defibrillators) and glucose meters occasionally end up in the EHR, data from consumer wearables and sensors and social media are currently not integrated into EHR systems. However, these data are increasingly being studied for their potential utility in health care, and may be integrated in the future. Adapted with permission from Datavant (58).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts